Betamethasone and Closure of Ductus Arteriosus

Launched by HOSPICES CIVILS DE LYON · Aug 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of betamethasone, a type of corticosteroid, to help close a heart condition in very premature infants called persistent ductus arteriosus (PDA). Normally, the ductus arteriosus is a blood vessel that closes after birth, but in some preterm babies, it remains open, which can lead to serious health issues like trouble breathing and other complications. Researchers want to see if giving betamethasone can help these babies breathe better and close the ductus arteriosus without needing surgery.

To participate in this trial, infants must have been born between January 2018 and December 2022, be less than 37 weeks old at birth, and be hospitalized at the Croix-Rousse hospital with a significant PDA. They also need to be receiving betamethasone for related breathing issues. Unfortunately, infants whose ductus arteriosus has already closed or who have passed away before or during the treatment will not be eligible. Parents can expect that their child will receive close monitoring and care throughout the study, with the hope of improving their respiratory health and reducing the need for more invasive treatments.

Gender

ALL

Eligibility criteria

• * Inclusion Criteria :
• • born between January 2018 and December 2022
• • at a gestational age below 37 weeks,
• • hospitalized in the Neonatal unit of Croix-Rousse hospital,
• • presenting a hemodynamically significant DA
• • treated by BTM for bronchopulmonary dysplasia
• * Exclusion Criteria :
• • Children having closed their ductus arteriosus before administration of the betamethasone course
• • Children who died before or during treatment.